Point72 Hong Kong Ltd Sells 969 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Point72 Hong Kong Ltd decreased its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 13.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,435 shares of the biotechnology company's stock after selling 969 shares during the period. Point72 Hong Kong Ltd's holdings in Axon Enterprise were worth $3,825,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. New Wave Wealth Advisors LLC bought a new position in shares of Axon Enterprise during the 4th quarter valued at about $40,000. Y.D. More Investments Ltd purchased a new stake in Axon Enterprise during the fourth quarter valued at about $45,000. Stonebridge Financial Group LLC purchased a new stake in Axon Enterprise during the fourth quarter valued at about $53,000. GPS Wealth Strategies Group LLC lifted its stake in Axon Enterprise by 74.1% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after buying an additional 40 shares in the last quarter. Finally, Berbice Capital Management LLC purchased a new stake in Axon Enterprise during the fourth quarter valued at about $59,000. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded up $4.79 during midday trading on Friday, hitting $733.18. The company had a trading volume of 419,101 shares, compared to its average volume of 759,084. The business's 50 day simple moving average is $584.61 and its two-hundred day simple moving average is $594.51. The stock has a market cap of $57.08 billion, a PE ratio of 189.45, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise, Inc. has a 1-year low of $273.52 and a 1-year high of $735.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. Axon Enterprise's quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the company posted $1.15 earnings per share. As a group, equities analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. The trade was a 0.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeri Williams sold 307 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the sale, the director now owns 1,627 shares in the company, valued at $899,275.44. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,764 shares of company stock valued at $14,856,635 over the last ninety days. 4.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on AXON. Needham & Company LLC upped their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. The Goldman Sachs Group upped their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday. Barclays upped their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Finally, Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $652.73.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.